Table 3.

Methylated HOXA9 as a diagnostic biomarker for lung cancer reported for the Discovery and Validation cohorts, respectively. HOXA9+ indicates detectable methylated HOXA9 (≥0.13%) in the bronchial lavage sample and hence a positive test. HOXA9- indicates a negative test with no detectable methylated HOXA9 (<0.13%). Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) are reported with 95% confidence intervals (CI).

	Discovery Cohort			Validation Cohort
Diagnosis	HOXA9+	HOXA9−	Total	HOXA9+	HOXA9−	Total
Lung cancer	49	18	67	40	10	50
No lung cancer	5	29	34	11	34	45
Total	54	47	101	51	44	95
Sensitivity (95% CI)	73.1% (60.9%–83.2%)			80.0% (66.3%–90.0%)
Specificity (95% CI)	85.3% (68.9%–95.0%)			75.6% (60.5%–87.1%)
PPV (95% CI)	90.7% (79.7%–96.9%)			78.4% (64.7%–88.7%)
NPV (95% CI)	61.7% (46.4%–75.5%)			77.3% (62.2%–88.5%)